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Abstract
Objective: To determine the quality of randomized controlled clinical trial (RCT) reports in diabetes research in Iran.
Design: Systematized review.
Methods: We included RCTs conducted on diabetes mellitus in Iran. Animal studies, educational interventions,
and non-randomized trials were excluded. We excluded duplicated publications reporting the same groups of
participants and intervention. Two independent reviewers identify all eligible articles specifically designed data
extraction form. We searched through international databases; Scopus, ProQuest, EBSCO, Science Direct, Web of
Science, Cochrane Library, PubMed; and national databases (In Persian language) such as Magiran, Scientific
Information Database (SID) and IranMedex from January 1995 to January of 2013 Two investigators assessed the
quality of reporting by CONSORT 2010 (Consolidated Standards of Reporting Trials) checklist statemen.t,.
Discrepancies were resolved by third reviewer consulting.
Results: One hundred and eight five (185) studies were included and appraised. Half of them (55.7 %) were
published in Iranian journals. Most (89.7 %) were parallel RCTs, and being performed on type2 diabetic patients
(77.8 %). Less than half of the CONSORT items (43.2 %) were reported in studies, totally. The reporting of randomization
and blinding were poor. A few studies 15.1 % mentioned the method of random sequence generation and strategy of
allocation concealment. And only 34.8 % of trials report how blinding was applied.
Conclusions: The findings of this study show that the quality of RCTs conducted in Iran in diabetes research seems
suboptimal and the reporting is also incomplete however an increasing trend of improvement can be seen over time.
Therefore, it is suggested Iranian researchers pay much more attention to design and methodological quality in
conducting and reporting of diabetes RCTs.
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Background
Diabetes mellitus as a chronic metabolic disorder has
reached epidemic proportions globally, placing a sub-
stantial burden on healthcare services. The number of
people with diabetes is growing rapidly worldwide [1, 2].
This trend even seems more in low income countries
[3]. Based on the data represented by the National Sur-
vey of Risk Factors for Non-Communicable Diseases of
Iran, it is estimated that 7.7 % of adults younger than
65 years had type 2 diabetes in 2008 [4].
Randomized controlled trials (RCTs) are the gold
standard for evaluating new therapies or strategies in
medicine [5]. However, the results of poorly designed or
poorly reported RCTs can yield biased results for routine
clinical practice and may impair the quality of pooled
analyses such as meta-analyses [6, 7]. Therefore, the
Consolidated Standards of Reporting Trials (CONSORT)
statement was developed by trial methodologists and
editors of biomedical journals in the mid-1990s for the
explicit purpose of improving clinical trial reporting [8].
The CONSORT statement, which provides guidance to
authors regarding essential items that should be in-
cluded in RCT reports, was updated in 2001 (and again
in 2010) to incorporate new elements [9, 10]. Although
the overall quality of RCTs reporting has been improved
internationally in medical sciences, to our best know-
ledge, there is no systematic assessment of the quality of
reporting of RCTs in diabetes trials in Iran according to
CONSORT.
Methods
Eligibility criteria
We included both parallel and cross-over RCTs conducted
on diabetes mellitus in Iran. Gestational Diabetes Mellitus
(GDM) trials, animal studies, educational interventions on
patients with diabetes, and other studies with different
designs (e.g., non-randomized controlled trials, before/
after studies, quasi experimental and observational stud-
ies) were excluded. There were restrictions on English and
Persian (Farsi) languages. We also excluded duplicated
publications reporting the same groups of participants.
Information sources
We identified relevant articles by a systematic search
through international databases; Scopus, ProQuest, EBSCO,
Science Direct, Web of Science, Cochrane Library,
PubMed; and national databases (In Persian language)
such as Magiran, Scientific Information Database (SID)
and IranMedex from January 1995 to January of 2013
(Additional file 1).
Quality assessment
Assessment of all included trials was carried out by two
independent reviewers, and the results were entered
directly into a preformatted Excel spreadsheet. Each
item was assigned a yes (Y, scored as 1) or no (N, scored
as 0) response depending on whether it was reported by
the author and each item was weighted with equal
importance. A total quality of reporting score, the
CONSORT score, was calculated by simply summing
the scores of the 37-item checklist, resulting in a pos-
sible range of 0–37. Thus, the maximum possible
score was 37 points. Each of the study articles was
then independently scored by two investigators. A
final score for each item on the checklist was re-
corded for each article after consensus was reached
through discussion between the two or in some cases,
after arbitration by a third investigator. The articles
were grouped by type of intervention. The main out-
come was the total percentage of articles that re-
ported each applicable section on the checklist. For
clarity, the Table 2 has been depicted which 37 items
would be expected to be reported. We compared the
total mean number and the percentages reported of
scores for each item of the CONSORT checklist be-
tween five interventions groups.
Results
Based on defined search strategy for this study, 414
articles identified. One hundred and seventy seven arti-
cles in first screening and fifty two articles in second
screening were excluded. Finally, 185 articles fulfilled
eligibility criteria and assessed for this systematic as-
sessment (Fig. 1).
Table 1 shows the general characteristics of all 185
studies. The study design of 116 articles (90 %) was par-
allel control group trial and the rest of studies were
cross over designed trial. The number of published RCTs
increased from 24 articles in 2005 to 61 articles in 2012.
Seventy five percent (75 %) of articles were about type 2
diabetes and the rest of studies were about either type 1
or both types of diabetes. We classified the interven-
tions into five groups. Four major categories were
pharmacological (medications), supplemental, herbal
and nutritional interventions. Other interventions
which performed on specific outcomes like diabetic
foot or diabetic retinopathy were named as “others”
group. The number of articles in each group was 54,
53, 30, 23 and 25, respectively.
The sample size of these studies ranged from 8 to
282 persons with the median of 62 but most of studies
(35 %) had 40 to 60 persons in their trials. The dur-
ation of studies varied depending on type of study and
intervention. This duration ranged from two days to
4 years. The median RCT duration was 12 weeks and
according to Table 1, the most of studies performed
between 10 and 15 weeks.
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Approximately all of studies (99 %) mentioned few
words in their articles about patients’ informed consent
or Institutional Review Board approval.
CONSORT- 2010 items according to five groups of in-
terventions have been presented in Table 2. Title is not
identified as a randomized trial in approximately in 67 %
of the articles and this rate is higher in supplemental
interventions (87 %). Most of the trials have provided
structured summary (87.6 %), scientific background
(98.4 %) and trial objectives (94.5 %) in their articles.
These proportions were similar in different interventions
groups. In items which were related to materials and
methods section of articles (3a to 12b), description of
trial design (69.7 %), eligibility criteria (97.3 %), descrip-
tion of interventions (93 %) and outcomes (88.6 %) and
statistical methods (97.8 %) had enough description. In
this part, the description of sample size calculation
(21.6) and methods of additional analysis (23.7 %) were
poorly reported but in nutritional interventions, add-
itional analysis received more attention than other inter-
ventions. However reporting and describing of related
items of CONSORT statement to randomization were
insufficient and inadequate, only 40 % of articles had
explanation about randomization. Only 33.5 % of trials
have reported who was blinded after assignment to in-
terventions. Participants and outcome assessors were
blinded in 39 articles while analyst was blinded in just
one trial. In addition, 36.2 % of articles mentioned de-
scription of the similarity of interventions.
Items 13a to 18 are related to results section of arti-
cles. In this section, approximately 19 % of articles used
participant flow diagram. The reasons of exclusions and
losses patients are explained in only 54.6 % of articles.
Eighty percent of articles included a table for showing
baseline demographic and characteristics for different
groups. Only twenty-two percent of trials had registra-
tion numbers. Full trial protocol could be accessed only
in fifteen percent and sources of funding and role of fun-
ders were mentioned only in approximately in fifty per-
cent of trails.
Discussion
Research in diabetes has been paid more attention in
recent years. With the development of evidence-based
medicine (EBM), RCTs have a high place in hierarchy
level to evaluate the efficacy and safety of any trials and
Fig. 1 CONSORT flow diagram
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play an important role in decision making for clinicians.
Adequate reporting of RCTs allows for easy determin-
ation of the RCT quality, which is important because
RCTs of poor quality may exaggerate the effects of
treatment and may potentially lead to erroneous con-
clusions [11–14].
To the best of our knowledge, this is the first
systematize assessment of randomized clinical trials pub-
lished in field of diabetes in Iran during writing this art-
icle based on CONSORT criteria. Results of the current
study indicated that the quality of randomized controlled
trials on diabetes needs improvement, especially in the
methods section and its adherence to CONSORT guide-
lines seems not enough.
Although there is some poor reporting of RCT in this
review, it is encouraging that this study shows an in-
creasing trend of improvement in the reporting quality
of RCTs (Fig. 2). This improvement has been seen more
in pharmacological and herbal medicine interventions
rather than nutritional interventions.
Although we observed an overall improvement in
RCT reporting over time, some methodological items
such as randomization, sequence generation, sample
size, allocation concealment, and blinding (29, 67,
51, 41, and 62 % of studies, respectively) remained
poorly reported.
Nevertheless, adequate reporting of trial methodology
is critical to avoid publication biases and to help readers
decide whether the study conclusions are valid. There-
fore, efforts should be made to improve the reporting of
CONSORT items in future publications.
The current study has a number of limitations. Our
analysis was limited to published studies, and therefore
it is potentially subject to publication bias. Indeed, it is
Table 1 The characteristic of studies based on the type of interventions
Pharmacological
Number (%)
Supplemental
Number (%)
Herbal
Number (%)
Nutritional
Number (%)
Others
Number (%)
Total
Number (%)
Study characteristics Parallel 50 (92.6) 51 (96.2) 28 (93.3) 12 (52.2) 25 (100) 166 (90)
cross-over 4 (7.4) 2 (3.8) 2 (6.7) 11 (47.8) 0 19 (10)
Year of publication <2005 9 (16.7) 6 (11.3) 4 (13.5) 4 (17.4) 1 (4) 24 (13)
2005–2006 7 (13) 1 (1.9) 2 (6.7) 2 (8.7) 2 (8) 14 (7)
2007–2008 9 (16.7) 15 (28.3) 5 (16.7) 4 (17.4) 5 (20) 38 (20)
2009–2010 13 (24.1) 14 (26.4) 7 (23.3) 3 (13) 11 (44) 48 (27)
>2011 16 (29.) 17 (32.1) 12 (40) 10 (43.5) 6 (24) 61 (33)
Type of diabetes Type 1 4 (7.4) 4 (7.5) 0 1 (4.3) 0 9 (5)
Type 2 40 (74.1) 46 (86.8) 29 (96.7) 21 (91.3) 8 (32) 137 (75)
Type 1 & 2 1 (1.9) 0 0 0 2 (8) 10 (5)
Not mentioned 9 (16.7) 3 (5.7) 1 (3.3) 1 (4.3) 15 (60) 29 (15)
Study duration (weeks) <1 2 (3.7) 1 (1.9) 1 (3.3) 0 0 4 (2)
1–5 6 (11.1) 0 7 (23.3) 2 (8.7) 4 (16) 19 (10)
5–10 10 (18.5) 22 (41.5) 14 (46.7) 12 (52.2) 3 (12) 51 (28)
10–15 20 (37) 24 (45.3) 4 (13.3) 3 (13) 6 (24) 57 (30)
15–20 6 (11) 2 (3.8) 3 (10) 4 (17.4) 4 (16) 19 (10)
20–25 7 (13) 1 (1.9) 1 (3.3) 1 (4.3) 7 (28) 17 (9)
>25 3 (5.6) 3 (5.7) 0 1 (4.3) 1 (4) 8 (4)
Estimation of sample size <20 3 (5.6) 0 3 (10) 6 (26.1) 0 12 (6)
20–40 12 (22.2) 10 (18.9) 2 (6.7) 4 (17.4) 4 (1) 32 (17)
40–60 17 (31.5) 18 (34) 12 (40) 8 (34.8) 8 (32) 63 (35)
60–80 10 (18.5) 13 (24.5) 7 (23.3) 4 (17.4) 8 (32) 42 (23)
80–100 4 (7.4) 8 (15.1) 5 (16.7) 1 (4.3) 2 (8) 20 (11)
>100 8 (14.8) 4 (7.5) 1 (3.3) 0 3 (12) 16 (8)
IRB approval, informed consent Yes 53 (98.1) 53 (100) 29 (96.7) 23 (100) 24 (96) 182 (99)
No 1 (1.9) 0 1 (3.3) 0 1 (4) 3 (1)
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known that some RCTs, especially those with negative
results, are never published. In addition, some RCTs
may have been poorly designed, or manuscripts may
have been so poorly written that they were rejected for
publication.
Furthermore, although we report on the adequacy of
reporting, as defined by the number of CONSORT-
mandated items reported, we are unable to comment on
the accuracy of reporting because we were unable to
compare the publications to the actual trial protocols.
Conclusion
In conclusion the findings of the current study indi-
cated that the quality of randomized controlled trials
Table 2 Quality of published articles in diabetes trials based on CONSORT items
Pharmacological Supplemental Herbal Nutritional Other Total
1a yes 15 (34.9 %) 7 (13 %) 15 (50 %) 8 (48.6 %) 17 (48.6 %) 62 (33.5)
1b yes 37 (86 %) 48 (88.9 %) 25 (83.3 %) 20 (87 %) 32 (91.4 %) 162 (87.6)
2a yes 42 (97.7 %) 53 (98.1 %) 29 (96.7 %) 23 (100 %) 35 (100 %) 182 (98.4)
2b yes 40 (93 %) 52 (96.3 %) 28 (93.3 %) 22 (95.7 %) 33 (94.3 %) 175 (94.5)
3a yes 32 (74.4 %) 38 (70.4 %) 22 (73.3 %) 15 (65.2 %) 22 (62.9 %) 129 (69.7)
3b yes 0 (0 %) 0 (0 %) 0 (0 %) 1 (4.3 %) 0 (0 %) 1 (0.5)
4a yes 42 (97.7 %) 51 (94.4 %) 29 (96.7 %) 23 (100 %) 35 (100 %) 180 (97.3)
4b yes 32 (74.4 %) 42 (77.8 %) 23 (76.7 %) 17 (73.9 %) 21 (60 %) 135 (73)
5 yes 40 (93 %) 46 (85.2 %) 29 (96.7 %) 22 (95.7 %) 35 (100 %) 172 (93)
6a yes 40 (93 %) 46 (85.2 %) 26 (86.7 %) 20 (87 %) 32 (91.4 %) 164 (88.6)
6b yes 0 (0 %) 0 (0 %) 0 (0 %) 2 (8.7 %) 0 (0 %) 2 (1.1)
7a yes 8 (18.6 %) 9 (16.7 %) 5 (16.7 %) 9 (39.1 %) 9 (25.7 %) 40 (21.6)
7b yes 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 1 (2.9 %) 1 (0.5)
8a yes 12 (27.9 %) 5 (9.3 %) 4 (13.3 %) 2 (8.7 %) 16 (45.7 %) 39 (21.1)
8b yes 10 (23.3 %) 10 (18.5 %) 7 (23.3 %) 2 (8.7 %) 7 (20 %) 36 (19.5)
9 yes 4 (9.3 %) 6 (11.1 %) 1 (3.3 %) 1 (4.3 %) 2 (5.7 %) 14 (7.6)
10 yes 6 (14 %) 8 (14.8 %) 2 (6.7 %) 3 (13 %) 4 (11.4 %) 23 (12.4)
11a yes 9 (20.9 %) 18 (33.3 %) 12 (40 %) 6 (26.1 %) 17 (48.6 %) 62 (33.5)
11b yes 10 (23.3 %) 27 (50 %) 16 (53.3 %) 5 (21.7 %) 9 (25.7 %) 67 (36.2)
12a yes 42 (97.7 %) 54 (100 %) 29 (96.7 %) 21 (91.3 %) 35 (100 %) 181 (97.8)
12b yes 8 (18.6 %) 12 (22.2 %) 5 (16.7 %) 10 (43.5 %) 9 (25.7 %) 44 (23.7)
13a yes 12 (27.9 %) 6 (11.1 %) 6 (20 %) 3 (13 %) 8 (22.9 %) 35 (18.9)
13b yes 23 (53.5 %) 26 (48.1 %) 19 (63.3 %) 14 (60.9 %) 19 (54.3 %) 101 (54.6)
14a yes 22 (51.2 %) 21 (38.9 %) 16 (53.3 %) 6 (26.1 %) 19 (54.3 %) 84 (45.4)
14b yes 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 2 (5.7 %) 2 (1.1)
15 yes 38 (88.4 %) 45 (83.3 %) 26 (86.7 %) 15 (65.2 %) 25 (71.4 %) 149 (80.5)
16 yes 14 (32.6 %) 3 (5.6 %) 8 (26.7 %) 4 (17.4 %) 13 (37.1 %) 42 (22.7)
17a yes 15 (34.9 %) 23 (42.6 %) 9 (30 %) 6 (26.1 %) 14 (40 %) 67 (36.2)
17b yes 0 (0 %) 0 (0 %) 1 (3.3 %) 0 (0 %) 1 (2.9 %) 2 (1.1)
18 yes 15 (34.9 %) 9 (16.7 %) 8 (26.7 %) 9 (39.1 %) 10 (28.6 %) 51 (27.6)
19 yes 22 (51.2 %) 13 (24.1 %) 13 (43.3 %) 5 (21.7 %) 26 (74.3 %) 79 (42.7)
20 yes 19 (44.2 %) 22 (40.7 %) 12 (40 %) 14 (60.9 %) 25 (71.4 %) 92 (49.7)
21 yes 5 (11.6 %) 14 (25.9 %) 10 (33.3 %) 7 (30.4 %) 13 (37.1 %) 49 (26.5)
22 yes 40 (93 %) 50 (92.6 %) 28 (93.3 %) 21 (91.3 %) 35 (100 %) 174 (94.1)
23 yes 10 (23.3 %) 12 (22.2 %) 9 (30 %) 5 (21.7 %) 5 (14.3 %) 41 (22.2)
24 yes 8 (18.6 %) 9 (16.7 %) 4 (13.3 %) 3 (13 %) 4 (11.4 %) 28 (15.1)
25 yes 22 (51.2 %) 32 (59.3 %) 19 (63.3 %) 12 (52.2 %) 7 (20 %) 92 (49.7)
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on diabetes published in Iran needs improvement, es-
pecially in the methods section and adherence to
CONSORT guidelines was not enough. Therefore, it is
suggested Iranian researchers pay more attention to
design and methodological quality in conducting and
reporting of diabetes RCTs.
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